Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, announced a second close of $30 million of its Series A financing. The round includes new investor Eli Lilly and Company (Lilly), in addition to existing investors OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors' Dementia Discovery Fund (DDF), Chugai Venture Fund, Alexandria Venture Investments, and PhiFund.

Proceeds from the second closing of Series A financing will be used to advance LTX-001 through an initial readout of its Phase 1b/2a clinical trial in schizophrenia patients, as well as progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 clinical trial in amyotrophic lateral sclerosis (ALS).